Literature DB >> 21575024

Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006.

Jennifer Mindell1, Maria Aresu, Paola Zaninotto, Emanuela Falaschetti, Neil Poulter.   

Abstract

OBJECTIVE: To evaluate blood lipid levels in the adult English population in 2006 and to report change in the use and efficacy of lipid-lowering treatment since 2003 after which time the general practitioner contract introduced a 'pay-per-performance' approach.
DESIGN: Cross-sectional surveys. PARTICIPANTS: Nationally representative sample of 14,142 noninstitutionalized adults (>16 years) living in England, partaking in the Health Survey for England 2006. MEASUREMENTS: Mean levels of total, HDL, non-HDL and total/HDL cholesterol ratio, prevalence of hypercholesterolaemia, use of lipid lowering agents and lipid levels and control rates among those on treatment.
RESULTS: Age-standardized mean cholesterol levels fell from 5·49 mM in men and 5·56 mM in women in 2003 to 5·26 and 5·37 mM, respectively, in 2006. In 2006, 59% of adults had a total cholesterol ≥ 5·0 mM and 11% reported lipid-lowering treatment, of whom 66% had a total cholesterol < 5·0 mM and 22% were < 4·0 mM. The majority of those with established coronary heart disease, stroke or diabetes but fewer than one quarter of those with hypertension or ≥ 20% estimated 10-year cardiovascular risk and no established CVD took lipid-lowering drugs. Lipid lowering treatment rates increased fivefold and control rates among the treated (to < 5·0 mM) more than doubled between 1998 and 2006. About one-third of those with established CVD or diabetes had cholesterol levels of < 4·0 mM.
CONCLUSIONS: Previously reported improvements in treatment and control rates between 1998 and 2003 continued between 2003 and 2006, with the biggest increases among those with established CVD and diabetes.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575024     DOI: 10.1111/j.1365-2265.2011.04094.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Persistent socioeconomic inequalities in cardiovascular risk factors in England over 1994-2008: a time-trend analysis of repeated cross-sectional data.

Authors:  Shaun Scholes; Madhavi Bajekal; Hande Love; Nathaniel Hawkins; Rosalind Raine; Martin O'Flaherty; Simon Capewell
Journal:  BMC Public Health       Date:  2012-02-14       Impact factor: 3.295

2.  Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.

Authors:  Kausik K Ray; Henry N Ginsberg; Michael H Davidson; Robert Pordy; Laurence Bessac; Pascal Minini; Robert H Eckel; Christopher P Cannon
Journal:  Circulation       Date:  2016-10-24       Impact factor: 29.690

Review 3.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

4.  Secular changes in mid-adulthood body mass index, waist circumference, and low HDL cholesterol between 1990, 2003, and 2018 in Great Britain.

Authors:  William Johnson; Tom Norris; Mark Hamer
Journal:  Eur J Clin Nutr       Date:  2020-09-16       Impact factor: 4.016

5.  Unmet need for hypercholesterolemia care in 35 low- and middle-income countries: A cross-sectional study of nationally representative surveys.

Authors:  Maja E Marcus; Cara Ebert; Pascal Geldsetzer; Michaela Theilmann; Brice Wilfried Bicaba; Glennis Andall-Brereton; Pascal Bovet; Farshad Farzadfar; Mongal Singh Gurung; Corine Houehanou; Mohammad-Reza Malekpour; Joao S Martins; Sahar Saeedi Moghaddam; Esmaeil Mohammadi; Bolormaa Norov; Sarah Quesnel-Crooks; Roy Wong-McClure; Justine I Davies; Mark A Hlatky; Rifat Atun; Till W Bärnighausen; Lindsay M Jaacks; Jennifer Manne-Goehler; Sebastian Vollmer
Journal:  PLoS Med       Date:  2021-10-25       Impact factor: 11.069

6.  Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018.

Authors:  Manuel E Machado-Duque; Diego Arturo Garcia; Melissa Hiromi Emura-Vélez; Andrés Gaviria-Mendoza; Jorge E Machado-Alba
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.